
## CLAIMS

1. Use of a compound represented by the following structural formula:



**Compound (I)** , or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease, disorder or condition mediated alone or in part by Janus Associated Kinases (JAKs);

wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium;

wherein the medicament is to be administered for (1) a first period of 8-24 weeks in an amount in the range of about 8 mg to about 32 mg per day, followed by (2) a second period of at least 8 weeks; wherein the medicament is to be administered in an amount per day that is 50 to 75 percent of the amount per day administered during the first period, such that the disease, disorder or condition mediated alone or in part by JAKs is treated.

2. The use of any one of claim 1, wherein in Compound (I), each position designated specifically as deuterium has at least 97% incorporation of deuterium.

3. The use of claim 1 or claim 2, wherein the disease, condition or disorder is selected from skin diseases such as proliferative, autoimmune and/or inflammatory skin disorders, psoriasis, atopic dermatitis, scleroderma, rosacea, skin cancers, dermatitis, dermatitis herpetiformis, dermatomyositis, vitiligo, hair loss disorders, contact dermatitis, xerosis, ichthyosis, hidradenitis suppurativa, urticaria, lichen planus, prurigo nodularis, vasculitis, cutaneous lupus erythematosus (CLE), and chronic idiopathic pruritus; hyperproliferative disorders or cancers including polycythemia vera, essential thrombocytopenia, and myelofibrosis; respiratory diseases such as

asthma, chronic obstructive pulmonary disease, chronic lung allograft dysfunction, e.g., bronchiolitis obliterans syndrome, pulmonary fibrosis, cystic fibrosis, rhinitis, bronchiolitis, byssinosis, pneumoconiosis, bronchiectasis, hypersensitivity pneumonitis, lung cancers, mesothelioma and sarcoidosis; gastrointestinal diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, retroperitoneal fibrosis, celiac disease and cancers; eye diseases such as myasthenia gravis, Sjogren's syndrome, conjunctivitis, scleritis, uveitis, dry eye syndrome, keratitis, iritis; systemic indications such as lupus, multiple sclerosis, rheumatoid arthritis, type I diabetes and complications from diabetes, cancers, ankylosing spondylitis and psoriatic arthritis; as well as other autoimmune diseases and indications where immunosuppression would be desirable, for example, to treat or prevent acute and/or chronic graft-versus-host disease (e.g., in organ transplantation).

4. The use of any one of claims 1-3, wherein, in the first period, the medicament is to be administered at about 16 mg/day, about 24 mg/day, or about 32 mg per day.

5. The use of any one of claims 1-4, wherein, in the second period, the medicament is to be administered at about 8 mg/day, about 12 mg/day, or about 16 mg per day.

6. The use of any one of claims 1-5, wherein in the first period, the medicament is to be administered at about 24 mg/day, and in the second period, the medicament is to be administered at about 16 mg/day.

7. The use of claim 6, wherein the about 24 mg/day of the medicament is to be administered once per day, and the about 16 mg/day is to be administered once per day.

8. The use of claim 6, wherein the about 24 mg/day of the medicament is to be administered as about 12 mg twice per day, and the about 16 mg/day of the compound or salt thereof is to be administered as about 8 mg twice per day.

9. The use of any one of claims 1-5, wherein in the first period, the medicament is to be administered at about 16 mg/day, and in the second period, the medicament is to be

administered at about 8 mg/day.

10. The use of any one of claims 1-6 or 9, wherein the medicament is to be administered once per day in the first period.

11. The use of any one of claims 1-6 or 9, wherein the medicament is to be administered twice per day in the first period.

12. The use of any one of claims 1-11, wherein the first period is about 8-12 weeks.

13. The use of any one of claims 1-11, wherein the first period is about 24 weeks.

14. The use of any one of claims 1-13, wherein the second period is at least 12 weeks.

15. The use of any one of claims 1-14, wherein the second period is at least 24 weeks.

16. The use of any one of claims 1-15, wherein the disease, condition or disorder is not a hair loss disorder.

17. The use of any one of claims 1-16, wherein the disease, condition or disorder is not alopecia areata.

18. The use of any one of claims 1-17, wherein the disease, condition or disorder is selected from skin diseases such as proliferative, autoimmune and/or inflammatory skin disorders, psoriasis, atopic dermatitis, scleroderma, rosacea, skin cancers, dermatitis, dermatitis herpetiformis, dermatomyositis, vitiligo, contact dermatitis, xerosis, ichthyosis, hidradenitis suppurativa, urticaria, lichen planus, prurigo nodularis, vasculitis, cutaneous lupus erythematosus (CLE), and chronic idiopathic pruritus; hyperproliferative disorders or cancers including polycythemia vera, essential thrombocytopenia, and myelofibrosis; respiratory diseases such as asthma, chronic obstructive pulmonary disease, chronic lung allograft dysfunction, e.g., bronchiolitis obliterans syndrome, pulmonary fibrosis, cystic fibrosis, rhinitis, bronchiolitis, byssinosis, pneumoconiosis, bronchiectasis, hypersensitivity

pneumonitis, lung cancers, mesothelioma and sarcoidosis; gastrointestinal diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, retroperitoneal fibrosis, celiac disease and cancers; eye diseases such as myasthenia gravis, Sjogren's syndrome, conjunctivitis, scleritis, uveitis, dry eye syndrome, keratitis, iritis; systemic indications such as lupus, multiple sclerosis, rheumatoid arthritis, type I diabetes and complications from diabetes, cancers, ankylosing spondylitis and psoriatic arthritis; as well as other autoimmune diseases and indications where immunosuppression would be desirable, for example, to treat or prevent acute and/or chronic graft-versus-host disease (e.g., in organ transplantation).

19. The use of any one of claims 1-18, wherein the medicament is to be administered orally.

20. The use of any one of Claims 1-19, wherein the medicament is to be administered in a pharmaceutical formulation which is a tablet.